Free Delivery on orders over £29*

Enacard Tablets for Dogs

Enacard Tablets for Dogs
1.0mg » Priced per Tablet
2.5mg » Priced per Tablet
5mg » Priced per Tablet
10mg » Priced per Tablet
20mg » Priced per Tablet

  • 1.0mg » Priced per Tablet £0.40
  • 2.5mg » Priced per Tablet £0.59
  • 5mg » Priced per Tablet £0.70
  • 10mg » Priced per Tablet £1.00
  • 20mg » Priced per Tablet £1.30

Selection of 5 products from

£0.40 to £1.30

Description

Enacard tablets are used to treat dogs with mild, moderate or severe heart failure. It has been shown to increase the ability to take exercise as well as life expectancy in affected dogs. It is particularly intended for dogs with leaking valves (mitral incompetence). This causes the heart to be less efficient as a pump, due to the reflux back through the valve when it is supposed to be closed. This condition develops most commonly in older, small breed dogs, often with no former history of heart trouble. Enacard also helps if there is a weakness of the heart muscle itself, causing it to stretch too much, making the heart wall weak and thin (dilated cardiomyopathy). Enacard is often combined with other heart medications, especially diuretics (which clear excess fluid from the body).

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

1.0mg » Priced per Tablet

Enacard Tablets for Dogs

Qualitative and quantitative composition

Active substance: Enalapril maleate.

Pharmaceutical form

Round, non-scored, biconvex, uncoated tablets. Colour coded according to dosage strength; 1 mg - green; 2.5 mg - blue; 5 mg - pink; 10 mg - yellow and 20 mg – white.

Clinical particulars

Target species

Dogs.

Indications for use

Treatment of mild, moderate and severe congestive heart failure in dogs caused by mitral regurgitation or dilated cardiomyopathy as an adjunctive therapy with diuretics. For improved exercise tolerance and increased survival in dogs with mild, moderate and severe heart failure.

Contra-indications

Do not use in any dog that has evidence of cardiac output failure e.g. aortic stenosis. The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established. Do not use with potassium-sparing diuretics.

Special warnings for each target species

See other sections.

Special precautions for use in animals

None known but see other sections.

Special precautions to be taken by the person administering the product

In case of accidental ingestion, seek urgent medical attention showing the product label to the doctor or nurse. Physicians should contact a Poison Control Centre for advice concerning cases of human consumption. Wash hands after use.

Adverse reactions

The product has been demonstrated to be generally well tolerated. In clinical studies, the overall incidence of side effects was not significantly greater with the product than with vehicle tablets. For the most part side effects have been mild and transient in nature and have not required discontinuation of therapy. Clinical signs reported include azotaemia, dizziness, drowsiness, hypotension, disorientation and incoordination.

Use during pregnancy, lactation or lay

The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established.

Interactions

Whilst all clinical data were generated in conjunction with furosemide, the product may be administered to dogs being treated with thiazide diuretics. Do not use the product with potassium-sparing diuretics.

Amounts to be administered and administration route

The product should be administered orally at a recommended dose rate of 0.5 mg/kg once daily. Individual dosages should be administered on the basis of bodyweight using the appropriate tablet(s) or combination of tablet sizes.

In the absence of a clinical response within 2 weeks following initiation of therapy with the product, the dose should be increased, depending on the patient’s response, up to a maximum of 0.5 mg/kg bodyweight administered twice daily. This dose titration may be performed over a two to four week period, or more rapidly if indicated by the presence of continuing signs of congestive heart failure. Dogs should be observed closely for 48 hours following initial dosing or an increase in dose.

Therapy with diuretics should be initiated at least one day prior to starting treatment with the product. Evaluation of the patient should include assessment of renal function prior to initiation of therapy and for 2 to 7 days after treatment with the product.

Renal function impairment in the target species

Pre-renal azotemia is usually a result of hypotension induced by impaired cardio-vascular performance. On occasion substances that deplete blood volume, such as diuretics, or which vasodilate, such as angiotensin-converting enzyme (ACE) inhibitors may contribute to lowering systemic blood pressure. This may create a hypotensive state or exacerbate an existing hypotensive situation and result in pre-renal azotemia.

Dogs with no detectable renal disease may develop minor and transient increases in blood urea nitrogen or serum creatinine when the product is administered concomitantly with a diuretic. Renal function should be monitored both before and 2 to 7 days after starting treatment with the product.

The dose of the diuretic and/or the product should be reduced or their use should be discontinued if signs of hypotension or azotemia develop or if the concentrations of blood urea nitrogen and/or serum creatinine increase significantly over pre-treatment levels. Periodic monitoring of renal function should be continued. Should clinical signs of overdosage occur (e.g. azotemia) after the dose is increased from once daily to twice daily, the dose should be decreased to once daily.

Overdose

The product at the recommended dose level has been shown to have an adequate margin of safety in dogs with heart failure. Normal dogs given 15 mg/kg/day for up to one year showed no adverse effects or changes.

Pharmacological particulars

Enacard is the maleate salt of enalapril, a derivative of two amino acids, L-alanine and L-proline. Enalapril is the ethyl ester of the parent diacid, enalaprilat. Following oral administration, enalapril is readily absorbed and then hydrolysed to enalaprilat, which is a highly specific, long-acting, non-sulphydryl angiotensin converting enzyme (ACE) inhibitor.

ATCvet code: QC09AA02

Pharmaceutical particulars

Excipients

Lactose monohydrate, Sodium bicarbonate, Maize starch, Pregelatinised maize starch, Magnesium stearate, Ferric oxide yellow (E172) (1 mg and 10 mg only), Indigo aluminium lake (E132) (1 mg and 2.5 mg only), Ferric oxide red (E172) (5mg only).

Major incompatibilities

No major incompatibility has been identified.

Shelf life

3 years.

Special precautions for storage

Do not store above 25 °C. Avoid transient temperatures above 50 °C.

Immediate packaging

The tablets are presented in an aluminium blister containing seven tablets, in cartons of four blisters.

Disposal

Any unused product or waste materials derived from such products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

Vm 08327/4194-98

Legal category

2.5mg » Priced per Tablet

Enacard Tablets for Dogs

Qualitative and quantitative composition

Active substance: Enalapril maleate.

Pharmaceutical form

Round, non-scored, biconvex, uncoated tablets. Colour coded according to dosage strength; 1 mg - green; 2.5 mg - blue; 5 mg - pink; 10 mg - yellow and 20 mg – white.

Clinical particulars

Target species

Dogs.

Indications for use

Treatment of mild, moderate and severe congestive heart failure in dogs caused by mitral regurgitation or dilated cardiomyopathy as an adjunctive therapy with diuretics. For improved exercise tolerance and increased survival in dogs with mild, moderate and severe heart failure.

Contra-indications

Do not use in any dog that has evidence of cardiac output failure e.g. aortic stenosis. The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established. Do not use with potassium-sparing diuretics.

Special warnings for each target species

See other sections.

Special precautions for use in animals

None known but see other sections.

Special precautions to be taken by the person administering the product

In case of accidental ingestion, seek urgent medical attention showing the product label to the doctor or nurse. Physicians should contact a Poison Control Centre for advice concerning cases of human consumption. Wash hands after use.

Adverse reactions

The product has been demonstrated to be generally well tolerated. In clinical studies, the overall incidence of side effects was not significantly greater with the product than with vehicle tablets. For the most part side effects have been mild and transient in nature and have not required discontinuation of therapy. Clinical signs reported include azotaemia, dizziness, drowsiness, hypotension, disorientation and incoordination.

Use during pregnancy, lactation or lay

The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established.

Interactions

Whilst all clinical data were generated in conjunction with furosemide, the product may be administered to dogs being treated with thiazide diuretics. Do not use the product with potassium-sparing diuretics.

Amounts to be administered and administration route

The product should be administered orally at a recommended dose rate of 0.5 mg/kg once daily. Individual dosages should be administered on the basis of bodyweight using the appropriate tablet(s) or combination of tablet sizes.

In the absence of a clinical response within 2 weeks following initiation of therapy with the product, the dose should be increased, depending on the patient’s response, up to a maximum of 0.5 mg/kg bodyweight administered twice daily. This dose titration may be performed over a two to four week period, or more rapidly if indicated by the presence of continuing signs of congestive heart failure. Dogs should be observed closely for 48 hours following initial dosing or an increase in dose.

Therapy with diuretics should be initiated at least one day prior to starting treatment with the product. Evaluation of the patient should include assessment of renal function prior to initiation of therapy and for 2 to 7 days after treatment with the product.

Renal function impairment in the target species

Pre-renal azotemia is usually a result of hypotension induced by impaired cardio-vascular performance. On occasion substances that deplete blood volume, such as diuretics, or which vasodilate, such as angiotensin-converting enzyme (ACE) inhibitors may contribute to lowering systemic blood pressure. This may create a hypotensive state or exacerbate an existing hypotensive situation and result in pre-renal azotemia.

Dogs with no detectable renal disease may develop minor and transient increases in blood urea nitrogen or serum creatinine when the product is administered concomitantly with a diuretic. Renal function should be monitored both before and 2 to 7 days after starting treatment with the product.

The dose of the diuretic and/or the product should be reduced or their use should be discontinued if signs of hypotension or azotemia develop or if the concentrations of blood urea nitrogen and/or serum creatinine increase significantly over pre-treatment levels. Periodic monitoring of renal function should be continued. Should clinical signs of overdosage occur (e.g. azotemia) after the dose is increased from once daily to twice daily, the dose should be decreased to once daily.

Overdose

The product at the recommended dose level has been shown to have an adequate margin of safety in dogs with heart failure. Normal dogs given 15 mg/kg/day for up to one year showed no adverse effects or changes.

Pharmacological particulars

Enacard is the maleate salt of enalapril, a derivative of two amino acids, L-alanine and L-proline. Enalapril is the ethyl ester of the parent diacid, enalaprilat. Following oral administration, enalapril is readily absorbed and then hydrolysed to enalaprilat, which is a highly specific, long-acting, non-sulphydryl angiotensin converting enzyme (ACE) inhibitor.

ATCvet code: QC09AA02

Pharmaceutical particulars

Excipients

Lactose monohydrate, Sodium bicarbonate, Maize starch, Pregelatinised maize starch, Magnesium stearate, Ferric oxide yellow (E172) (1 mg and 10 mg only), Indigo aluminium lake (E132) (1 mg and 2.5 mg only), Ferric oxide red (E172) (5mg only).

Major incompatibilities

No major incompatibility has been identified.

Shelf life

3 years.

Special precautions for storage

Do not store above 25 °C. Avoid transient temperatures above 50 °C.

Immediate packaging

The tablets are presented in an aluminium blister containing seven tablets, in cartons of four blisters.

Disposal

Any unused product or waste materials derived from such products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

Vm 08327/4194-98

Legal category

5mg » Priced per Tablet

Enacard Tablets for Dogs

Qualitative and quantitative composition

Active substance: Enalapril maleate.

Pharmaceutical form

Round, non-scored, biconvex, uncoated tablets. Colour coded according to dosage strength; 1 mg - green; 2.5 mg - blue; 5 mg - pink; 10 mg - yellow and 20 mg – white.

Clinical particulars

Target species

Dogs.

Indications for use

Treatment of mild, moderate and severe congestive heart failure in dogs caused by mitral regurgitation or dilated cardiomyopathy as an adjunctive therapy with diuretics. For improved exercise tolerance and increased survival in dogs with mild, moderate and severe heart failure.

Contra-indications

Do not use in any dog that has evidence of cardiac output failure e.g. aortic stenosis. The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established. Do not use with potassium-sparing diuretics.

Special warnings for each target species

See other sections.

Special precautions for use in animals

None known but see other sections.

Special precautions to be taken by the person administering the product

In case of accidental ingestion, seek urgent medical attention showing the product label to the doctor or nurse. Physicians should contact a Poison Control Centre for advice concerning cases of human consumption. Wash hands after use.

Adverse reactions

The product has been demonstrated to be generally well tolerated. In clinical studies, the overall incidence of side effects was not significantly greater with the product than with vehicle tablets. For the most part side effects have been mild and transient in nature and have not required discontinuation of therapy. Clinical signs reported include azotaemia, dizziness, drowsiness, hypotension, disorientation and incoordination.

Use during pregnancy, lactation or lay

The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established.

Interactions

Whilst all clinical data were generated in conjunction with furosemide, the product may be administered to dogs being treated with thiazide diuretics. Do not use the product with potassium-sparing diuretics.

Amounts to be administered and administration route

The product should be administered orally at a recommended dose rate of 0.5 mg/kg once daily. Individual dosages should be administered on the basis of bodyweight using the appropriate tablet(s) or combination of tablet sizes.

In the absence of a clinical response within 2 weeks following initiation of therapy with the product, the dose should be increased, depending on the patient’s response, up to a maximum of 0.5 mg/kg bodyweight administered twice daily. This dose titration may be performed over a two to four week period, or more rapidly if indicated by the presence of continuing signs of congestive heart failure. Dogs should be observed closely for 48 hours following initial dosing or an increase in dose.

Therapy with diuretics should be initiated at least one day prior to starting treatment with the product. Evaluation of the patient should include assessment of renal function prior to initiation of therapy and for 2 to 7 days after treatment with the product.

Renal function impairment in the target species

Pre-renal azotemia is usually a result of hypotension induced by impaired cardio-vascular performance. On occasion substances that deplete blood volume, such as diuretics, or which vasodilate, such as angiotensin-converting enzyme (ACE) inhibitors may contribute to lowering systemic blood pressure. This may create a hypotensive state or exacerbate an existing hypotensive situation and result in pre-renal azotemia.

Dogs with no detectable renal disease may develop minor and transient increases in blood urea nitrogen or serum creatinine when the product is administered concomitantly with a diuretic. Renal function should be monitored both before and 2 to 7 days after starting treatment with the product.

The dose of the diuretic and/or the product should be reduced or their use should be discontinued if signs of hypotension or azotemia develop or if the concentrations of blood urea nitrogen and/or serum creatinine increase significantly over pre-treatment levels. Periodic monitoring of renal function should be continued. Should clinical signs of overdosage occur (e.g. azotemia) after the dose is increased from once daily to twice daily, the dose should be decreased to once daily.

Overdose

The product at the recommended dose level has been shown to have an adequate margin of safety in dogs with heart failure. Normal dogs given 15 mg/kg/day for up to one year showed no adverse effects or changes.

Pharmacological particulars

Enacard is the maleate salt of enalapril, a derivative of two amino acids, L-alanine and L-proline. Enalapril is the ethyl ester of the parent diacid, enalaprilat. Following oral administration, enalapril is readily absorbed and then hydrolysed to enalaprilat, which is a highly specific, long-acting, non-sulphydryl angiotensin converting enzyme (ACE) inhibitor.

ATCvet code: QC09AA02

Pharmaceutical particulars

Excipients

Lactose monohydrate, Sodium bicarbonate, Maize starch, Pregelatinised maize starch, Magnesium stearate, Ferric oxide yellow (E172) (1 mg and 10 mg only), Indigo aluminium lake (E132) (1 mg and 2.5 mg only), Ferric oxide red (E172) (5mg only).

Major incompatibilities

No major incompatibility has been identified.

Shelf life

3 years.

Special precautions for storage

Do not store above 25 °C. Avoid transient temperatures above 50 °C.

Immediate packaging

The tablets are presented in an aluminium blister containing seven tablets, in cartons of four blisters.

Disposal

Any unused product or waste materials derived from such products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

Vm 08327/4194-98

Legal category

10mg » Priced per Tablet

Enacard Tablets for Dogs

Qualitative and quantitative composition

Active substance: Enalapril maleate.

Pharmaceutical form

Round, non-scored, biconvex, uncoated tablets. Colour coded according to dosage strength; 1 mg - green; 2.5 mg - blue; 5 mg - pink; 10 mg - yellow and 20 mg – white.

Clinical particulars

Target species

Dogs.

Indications for use

Treatment of mild, moderate and severe congestive heart failure in dogs caused by mitral regurgitation or dilated cardiomyopathy as an adjunctive therapy with diuretics. For improved exercise tolerance and increased survival in dogs with mild, moderate and severe heart failure.

Contra-indications

Do not use in any dog that has evidence of cardiac output failure e.g. aortic stenosis. The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established. Do not use with potassium-sparing diuretics.

Special warnings for each target species

See other sections.

Special precautions for use in animals

None known but see other sections.

Special precautions to be taken by the person administering the product

In case of accidental ingestion, seek urgent medical attention showing the product label to the doctor or nurse. Physicians should contact a Poison Control Centre for advice concerning cases of human consumption. Wash hands after use.

Adverse reactions

The product has been demonstrated to be generally well tolerated. In clinical studies, the overall incidence of side effects was not significantly greater with the product than with vehicle tablets. For the most part side effects have been mild and transient in nature and have not required discontinuation of therapy. Clinical signs reported include azotaemia, dizziness, drowsiness, hypotension, disorientation and incoordination.

Use during pregnancy, lactation or lay

The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established.

Interactions

Whilst all clinical data were generated in conjunction with furosemide, the product may be administered to dogs being treated with thiazide diuretics. Do not use the product with potassium-sparing diuretics.

Amounts to be administered and administration route

The product should be administered orally at a recommended dose rate of 0.5 mg/kg once daily. Individual dosages should be administered on the basis of bodyweight using the appropriate tablet(s) or combination of tablet sizes.

In the absence of a clinical response within 2 weeks following initiation of therapy with the product, the dose should be increased, depending on the patient’s response, up to a maximum of 0.5 mg/kg bodyweight administered twice daily. This dose titration may be performed over a two to four week period, or more rapidly if indicated by the presence of continuing signs of congestive heart failure. Dogs should be observed closely for 48 hours following initial dosing or an increase in dose.

Therapy with diuretics should be initiated at least one day prior to starting treatment with the product. Evaluation of the patient should include assessment of renal function prior to initiation of therapy and for 2 to 7 days after treatment with the product.

Renal function impairment in the target species

Pre-renal azotemia is usually a result of hypotension induced by impaired cardio-vascular performance. On occasion substances that deplete blood volume, such as diuretics, or which vasodilate, such as angiotensin-converting enzyme (ACE) inhibitors may contribute to lowering systemic blood pressure. This may create a hypotensive state or exacerbate an existing hypotensive situation and result in pre-renal azotemia.

Dogs with no detectable renal disease may develop minor and transient increases in blood urea nitrogen or serum creatinine when the product is administered concomitantly with a diuretic. Renal function should be monitored both before and 2 to 7 days after starting treatment with the product.

The dose of the diuretic and/or the product should be reduced or their use should be discontinued if signs of hypotension or azotemia develop or if the concentrations of blood urea nitrogen and/or serum creatinine increase significantly over pre-treatment levels. Periodic monitoring of renal function should be continued. Should clinical signs of overdosage occur (e.g. azotemia) after the dose is increased from once daily to twice daily, the dose should be decreased to once daily.

Overdose

The product at the recommended dose level has been shown to have an adequate margin of safety in dogs with heart failure. Normal dogs given 15 mg/kg/day for up to one year showed no adverse effects or changes.

Pharmacological particulars

Enacard is the maleate salt of enalapril, a derivative of two amino acids, L-alanine and L-proline. Enalapril is the ethyl ester of the parent diacid, enalaprilat. Following oral administration, enalapril is readily absorbed and then hydrolysed to enalaprilat, which is a highly specific, long-acting, non-sulphydryl angiotensin converting enzyme (ACE) inhibitor.

ATCvet code: QC09AA02

Pharmaceutical particulars

Excipients

Lactose monohydrate, Sodium bicarbonate, Maize starch, Pregelatinised maize starch, Magnesium stearate, Ferric oxide yellow (E172) (1 mg and 10 mg only), Indigo aluminium lake (E132) (1 mg and 2.5 mg only), Ferric oxide red (E172) (5mg only).

Major incompatibilities

No major incompatibility has been identified.

Shelf life

3 years.

Special precautions for storage

Do not store above 25 °C. Avoid transient temperatures above 50 °C.

Immediate packaging

The tablets are presented in an aluminium blister containing seven tablets, in cartons of four blisters.

Disposal

Any unused product or waste materials derived from such products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

Vm 08327/4194-98

Legal category

20mg » Priced per Tablet

Enacard Tablets for Dogs

Qualitative and quantitative composition

Active substance: Enalapril maleate.

Pharmaceutical form

Round, non-scored, biconvex, uncoated tablets. Colour coded according to dosage strength; 1 mg - green; 2.5 mg - blue; 5 mg - pink; 10 mg - yellow and 20 mg – white.

Clinical particulars

Target species

Dogs.

Indications for use

Treatment of mild, moderate and severe congestive heart failure in dogs caused by mitral regurgitation or dilated cardiomyopathy as an adjunctive therapy with diuretics. For improved exercise tolerance and increased survival in dogs with mild, moderate and severe heart failure.

Contra-indications

Do not use in any dog that has evidence of cardiac output failure e.g. aortic stenosis. The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established. Do not use with potassium-sparing diuretics.

Special warnings for each target species

See other sections.

Special precautions for use in animals

None known but see other sections.

Special precautions to be taken by the person administering the product

In case of accidental ingestion, seek urgent medical attention showing the product label to the doctor or nurse. Physicians should contact a Poison Control Centre for advice concerning cases of human consumption. Wash hands after use.

Adverse reactions

The product has been demonstrated to be generally well tolerated. In clinical studies, the overall incidence of side effects was not significantly greater with the product than with vehicle tablets. For the most part side effects have been mild and transient in nature and have not required discontinuation of therapy. Clinical signs reported include azotaemia, dizziness, drowsiness, hypotension, disorientation and incoordination.

Use during pregnancy, lactation or lay

The product is not recommended for use in pregnant bitches. Safety in breeding dogs has not been established.

Interactions

Whilst all clinical data were generated in conjunction with furosemide, the product may be administered to dogs being treated with thiazide diuretics. Do not use the product with potassium-sparing diuretics.

Amounts to be administered and administration route

The product should be administered orally at a recommended dose rate of 0.5 mg/kg once daily. Individual dosages should be administered on the basis of bodyweight using the appropriate tablet(s) or combination of tablet sizes.

In the absence of a clinical response within 2 weeks following initiation of therapy with the product, the dose should be increased, depending on the patient’s response, up to a maximum of 0.5 mg/kg bodyweight administered twice daily. This dose titration may be performed over a two to four week period, or more rapidly if indicated by the presence of continuing signs of congestive heart failure. Dogs should be observed closely for 48 hours following initial dosing or an increase in dose.

Therapy with diuretics should be initiated at least one day prior to starting treatment with the product. Evaluation of the patient should include assessment of renal function prior to initiation of therapy and for 2 to 7 days after treatment with the product.

Renal function impairment in the target species

Pre-renal azotemia is usually a result of hypotension induced by impaired cardio-vascular performance. On occasion substances that deplete blood volume, such as diuretics, or which vasodilate, such as angiotensin-converting enzyme (ACE) inhibitors may contribute to lowering systemic blood pressure. This may create a hypotensive state or exacerbate an existing hypotensive situation and result in pre-renal azotemia.

Dogs with no detectable renal disease may develop minor and transient increases in blood urea nitrogen or serum creatinine when the product is administered concomitantly with a diuretic. Renal function should be monitored both before and 2 to 7 days after starting treatment with the product.

The dose of the diuretic and/or the product should be reduced or their use should be discontinued if signs of hypotension or azotemia develop or if the concentrations of blood urea nitrogen and/or serum creatinine increase significantly over pre-treatment levels. Periodic monitoring of renal function should be continued. Should clinical signs of overdosage occur (e.g. azotemia) after the dose is increased from once daily to twice daily, the dose should be decreased to once daily.

Overdose

The product at the recommended dose level has been shown to have an adequate margin of safety in dogs with heart failure. Normal dogs given 15 mg/kg/day for up to one year showed no adverse effects or changes.

Pharmacological particulars

Enacard is the maleate salt of enalapril, a derivative of two amino acids, L-alanine and L-proline. Enalapril is the ethyl ester of the parent diacid, enalaprilat. Following oral administration, enalapril is readily absorbed and then hydrolysed to enalaprilat, which is a highly specific, long-acting, non-sulphydryl angiotensin converting enzyme (ACE) inhibitor.

ATCvet code: QC09AA02

Pharmaceutical particulars

Excipients

Lactose monohydrate, Sodium bicarbonate, Maize starch, Pregelatinised maize starch, Magnesium stearate, Ferric oxide yellow (E172) (1 mg and 10 mg only), Indigo aluminium lake (E132) (1 mg and 2.5 mg only), Ferric oxide red (E172) (5mg only).

Major incompatibilities

No major incompatibility has been identified.

Shelf life

3 years.

Special precautions for storage

Do not store above 25 °C. Avoid transient temperatures above 50 °C.

Immediate packaging

The tablets are presented in an aluminium blister containing seven tablets, in cartons of four blisters.

Disposal

Any unused product or waste materials derived from such products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

Vm 08327/4194-98

Legal category

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (3)

Q & A

Below are some recent questions we've received regarding Enacard Tablets for Dogs, including answers from our team.

6 February 2019 at 10:01am

Which value

sg

which value of enacard do I need for a dog of abou 12 kg

  • Brand Manager

Hello,

Your vet will make a decision about which strength your dog needs and write a prescription for them, but the normal dose stated on the data sheet is 0.5mg/kg. At the standard rate your dog would need 6mg, although other factors can affect the dose your vet feels is most appropriate to give. It is likely that your dog would be prescribed a combination of two strengths, to make the most suitable dose.

The best thing to do would be to speak to your vet, and you can send us a copy of your prescription, and we can then supply you with this medication.

Kind regards,

Danielle